Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement

August 30, 2017 updated by: Gang Wang, MD, Capital Medical University

A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks

Although treatment guidelines manifest that antidepressant response usually appear with a delay of several weeks and suggest that treatment should be changed if a partial response has not occurred after 4~6 week, these beliefs are no longer held by experts, and a new concept is raised that the first 2 weeks of treatment may be a useful strategy for improving the management of depression. New evidence indicates that early treatment response can be predicted with high sensitivity after 2 weeks of treatment in patients with major depressive disorder (MDD).

Early improvement not only predicted response or remission, but also that lack of improvement was associated with little chance of response if the treatment strategy remained unchanged. The criterion of a 20% score reduction has been chosen as an early indicator of improvement because it can be reliably measured in clinical trials and translates into a clinically relevant change in the severity of depressive symptoms.

Antidepressants that enhance both serotonergic and noradrenergic neurotransmission may be more effective than selective serotonin reuptake inhibitors (SSRIs) for acute-phase therapy of major depressive disorder. As a noradrenergic and specific serotonergic antidepressant, the antidepressive mechanism of mirtazapine is quite superior to SSRI and in particular has been suggested to have a faster onset of action than SSRIs in MDD patients.

The aim of this study is to provide physicians with further information regarding early improvement and the effectiveness of mirtazapine combined with a SSRI antidepressant therapy in nonresponders.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Mirtazapine has significant advantages in response and remission rates compared with various SSRIs in double-blind treatment. Mirtazapine combined with SSRIs or venlafaxine was also found to be one of the more effective and successful strategy for nonresponders in MDD. The investigators hypothesized that mirtazapine as adjunctive treatment to paroxetine can boost the onset time and also can improve the antidepression action of SSRIs in patients without early improvement.

The aim of this study is to provide physicians with further information regarding early improvement and mirtazapine combined with a SSRI antidepressant therapy in nonresponders, by providing a comparison of depressive symptoms outcomes associated with adjunctive mirtazapine or mono- paroxetine in MDD patients who have previously been treated with paroxetine for 2 weeks and who have not attained improvement. Paroxetine has been chosen as a comparator because it is a widely-used and relatively well-tolerated SSRI antidepressant.

The study is designed as a multi-center, randomized, double-blind, active-controlled trial in subjects with MDD.

Patients will be male or female, 18 to 60 years of age, inclusive, outpatient or inpatient status, with diagnosis of major depressive episode (single or recurrent) by DSM-IV. The patients should also have HAMD-17 total score ≥ 20,a HAMD-17 Item 1(depressed mood) score ≥ 2 at enrollment in open-label preliminary phase.

It will consist of 2 phases. An open-label preliminary phase lasts for 2 weeks, during which paroxetine is titrated up to 20mg/day (Day 5). At Week 2, patients will be evaluated by HAMD-17. The patients who have achieved early improvement (the decrease of HAMD-17 total score ≥ 20%) will be discontinued. The patients who have not achieved early improvement (the decrease of HAMD-17 total score < 20%), will be randomized into three treatment arms [1.Mirtazapine (30mg/d); 2.Paroxetine (20mg/d); 3.Mirtazapine (30mg/d) +Paroxetine(20mg/d)]. In double-blind treatment phase (consist of 6 weeks), patients will be evaluated at Week 3, 4, 6 and 8.

Primary efficacy measure will be assessed based on the decrease of HAMD-17 from randomization (Week 2) to endpoint (Week 8). CGI-I and CGI-S will be used as secondary efficacy measures throughout this phase.

The safety in this study will be assessed by adverse event reporting, clinical laboratory measurements and physical examinations.

Up to 540 patients will enter into Open-label Phase in order to yield approximately 200 evaluable patients in Randomization Phase.

Study Type

Interventional

Enrollment (Actual)

525

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100088
        • Beijing Anding Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Has given written informed consent.
  2. Male or female outpatients aged at least 18 years and not more than 60 years.
  3. Has a diagnosis of major depressive disorder by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.
  4. HAMD-17 ≥ 20 and HAMD-17 Item 1(depressed mood) score ≥2 at enrolment in open-label preliminary phase.

Exclusion Criteria:

  1. Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.
  2. Current Axis I primary psychiatric diagnosis other than major depressive disorder.
  3. Organic mental disease, including mental retardation.
  4. History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.
  5. Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.
  6. Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.
  7. Use of antipsychotics or mood stabilizers within 5 days prior to screening.
  8. Has received depot antipsychotic medication within one cycle prior to screening.
  9. Known allergy or lack of response to mirtazapine.
  10. Has received ECT or MECT within 3 months prior to screening.
  11. Significant risk of suicidal and/or self-harm behaviors.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Add-on therapy
mirtazapine 30mg QD and paroxetine 20mg QD
Drug: mirtazapine
mirtazapine 30mg QD
Other Names:
  • Remeron
Drug: paroxetine 20mg QD
paroxetine 20mg QD
Other Names:
  • Seroxat
Active Comparator: mirtazapine monotherapy
mirtazapine 30mg QD
Drug: mirtazapine
mirtazapine 30mg QD
Other Names:
  • Remeron
Active Comparator: paroxetine monotherapy
paroxetine 20mg QD
Drug: paroxetine 20mg QD
paroxetine 20mg QD
Other Names:
  • Seroxat

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptoms Improvement by HAMD-17
Time Frame: From randomization (Week 2) to endpoint(Week 8)
Change of 17-item Hamilton Depression Scale (HAMD-17) total score
From randomization (Week 2) to endpoint(Week 8)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-reported improvement by QIDS-SR
Time Frame: From randomization (Week 2) to endpoint(Week 8)
Change of Quick Inventory of Depressive Symptomatology-self report (QIDS-SR) total score
From randomization (Week 2) to endpoint(Week 8)
Remission rate by HAMD-17
Time Frame: From randomization (Week 2) to endpoint(Week 8)
The proportion of subjects at endpoint with HAMD-17 total score ≤7
From randomization (Week 2) to endpoint(Week 8)
Remission rate by QIDS-SR
Time Frame: From randomization (Week 2) to endpoint(Week 8)
The proportion of subjects at endpoint with QIDS-SR total score ≤5
From randomization (Week 2) to endpoint(Week 8)
Response rate HAMD-17
Time Frame: From randomization (Week 2) to endpoint(Week 8)
The proportion of subjects at endpoint with the reduction of HAMD-17 total score >=50%
From randomization (Week 2) to endpoint(Week 8)
Response rate by QIDS-SR
Time Frame: From randomization (Week 2) to endpoint(Week 8)
The proportion of subjects at endpoint with the reduction of QIDS-SR total score >=50%
From randomization (Week 2) to endpoint(Week 8)
Clinical Global Impression-improvement
Time Frame: Endpoint(Week 8)
The proportion of subjects at endpoint with CGI-I as "much improved" or "very much improved"
Endpoint(Week 8)
Clinical Global Impression- severity
Time Frame: From randomization (Week 2) to endpoint(Week 8)
Change of CGI-S total score
From randomization (Week 2) to endpoint(Week 8)
Safety outcome 1
Time Frame: From enrollment to endpoint (Week 8)
The incidence and nature of overall adverse events
From enrollment to endpoint (Week 8)
Safety outcome 2
Time Frame: From enrollment to endpoint (Week 8)
The incidence and nature of drug-related adverse events
From enrollment to endpoint (Week 8)
Drop-off rate due to adverse events
Time Frame: From randomization (Week 2) to endpoint(Week 8)
The number of subject withdrawal due to adverse events during double-blind phase
From randomization (Week 2) to endpoint(Week 8)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Capital Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2012

Primary Completion (Actual)

August 24, 2016

Study Completion (Actual)

August 24, 2016

Study Registration Dates

First Submitted

August 9, 2011

First Submitted That Met QC Criteria

October 24, 2011

First Posted (Estimate)

October 25, 2011

Study Record Updates

Last Update Posted (Actual)

August 31, 2017

Last Update Submitted That Met QC Criteria

August 30, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MISP # 39888

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depression

Clinical Trials on mirtazapine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe